These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
570 related articles for article (PubMed ID: 19617342)
1. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342 [TBL] [Abstract][Full Text] [Related]
2. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729 [TBL] [Abstract][Full Text] [Related]
3. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice. McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760 [TBL] [Abstract][Full Text] [Related]
4. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates. Razumienko E; Dryden L; Scollard D; Reilly RM Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982 [TBL] [Abstract][Full Text] [Related]
5. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates. Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962 [TBL] [Abstract][Full Text] [Related]
6. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates. Razumienko EJ; Scollard DA; Reilly RM J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164 [TBL] [Abstract][Full Text] [Related]
7. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts. Costantini DL; McLarty K; Lee H; Done SJ; Vallis KA; Reilly RM J Nucl Med; 2010 Jul; 51(7):1084-91. PubMed ID: 20554744 [TBL] [Abstract][Full Text] [Related]
8. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548 [TBL] [Abstract][Full Text] [Related]
10. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207 [TBL] [Abstract][Full Text] [Related]
11. Tumor uptake and tumor/blood ratios for [ Al-Saden N; Cai Z; Reilly RM Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575 [TBL] [Abstract][Full Text] [Related]
12. Development and preclinical studies of Lam K; Chan C; Reilly RM MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707 [TBL] [Abstract][Full Text] [Related]
13. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with Al-Saden N; Lam K; Chan C; Reilly RM Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952 [TBL] [Abstract][Full Text] [Related]
14. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. Chen P; Cameron R; Wang J; Vallis KA; Reilly RM J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194 [TBL] [Abstract][Full Text] [Related]
15. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Cornelissen B; McLarty K; Kersemans V; Reilly RM Nucl Med Biol; 2008 Aug; 35(6):645-53. PubMed ID: 18678349 [TBL] [Abstract][Full Text] [Related]
16. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments. Tang Y; Wang J; Scollard DA; Mondal H; Holloway C; Kahn HJ; Reilly RM Nucl Med Biol; 2005 Jan; 32(1):51-8. PubMed ID: 15691661 [TBL] [Abstract][Full Text] [Related]
17. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [ Facca VJ; Al-Saden N; Ku A; Reilly RM Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914 [TBL] [Abstract][Full Text] [Related]
18. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer. Scollard DA; Chan C; Holloway CM; Reilly RM Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136 [TBL] [Abstract][Full Text] [Related]
19. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. McLarty K; Cornelissen B; Scollard DA; Done SJ; Chun K; Reilly RM Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):81-93. PubMed ID: 18712381 [TBL] [Abstract][Full Text] [Related]